234 related articles for article (PubMed ID: 10502254)
1. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
Yeo W; Steinberg JL; Tam JS; Chan PK; Leung NW; Lam KC; Mok TS; Johnson PJ
J Med Virol; 1999 Nov; 59(3):263-9. PubMed ID: 10502254
[TBL] [Abstract][Full Text] [Related]
2. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
Yeo W; Chan PK; Zhong S; Ho WM; Steinberg JL; Tam JS; Hui P; Leung NW; Zee B; Johnson PJ
J Med Virol; 2000 Nov; 62(3):299-307. PubMed ID: 11055239
[TBL] [Abstract][Full Text] [Related]
3. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
Cil T; Altintas A; Pasa S; Bayan K; Ozekinci T; Isikdogan A
Leuk Lymphoma; 2008 May; 49(5):939-47. PubMed ID: 18464113
[TBL] [Abstract][Full Text] [Related]
4. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Rossi G; Pelizzari A; Motta M; Puoti M
Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.
Steinberg JL; Yeo W; Zhong S; Chan JY; Tam JS; Chan PK; Leung NW; Johnson PJ
J Med Virol; 2000 Mar; 60(3):249-55. PubMed ID: 10630955
[TBL] [Abstract][Full Text] [Related]
6. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy.
Marrone A; Capoluongo N; D'Amore C; Pisaturo M; Esposito M; Guastafierro S; Siniscalchi I; Macera M; Boemio A; Onorato L; Rinaldi L; Minichini C; Adinolfi LE; Sagnelli E; Mastrullo L; Coppola N
J Viral Hepat; 2018 Feb; 25(2):198-204. PubMed ID: 29029365
[TBL] [Abstract][Full Text] [Related]
7. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
8. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
[TBL] [Abstract][Full Text] [Related]
9. Preemptive adefovir versus lamivudine for prevention of hepatitis B reactivation in chronic hepatitis B patients undergoing chemotherapy.
Ho EY; Yau T; Rousseau F; Heathcote EJ; Lau GK
Hepatol Int; 2015 Apr; 9(2):224-30. PubMed ID: 25788197
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
[TBL] [Abstract][Full Text] [Related]
12. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
14. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin's lymphoma.
Kim JS; Hahn JS; Park SY; Kim Y; Park IH; Lee CK; Cheong JW; Lee ST; Min YH
Yonsei Med J; 2007 Feb; 48(1):78-89. PubMed ID: 17326249
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.
Talotta R; Atzeni F; Sarzi Puttini P
BMC Pharmacol Toxicol; 2016 Apr; 17():17. PubMed ID: 27098382
[TBL] [Abstract][Full Text] [Related]
17. [Nucleos(t)ides as prophylaxis for the reactivation of hepatitis B virus in immunosuppressed patients].
Fan LY; Zhou Z; Zhong S; Ling N; Wang ZY; Shi XF; Zhang DZ; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):429-33. PubMed ID: 19567021
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma.
Liao CA; Lee CM; Wu HC; Wang MC; Lu SN; Eng HL
Br J Haematol; 2002 Jan; 116(1):166-9. PubMed ID: 11841412
[TBL] [Abstract][Full Text] [Related]
20. Case report: lamivudine therapy for submassive hepatic necrosis due to reactivation of hepatitis B following chemotherapy.
Maguire CM; Crawford DH; Hourigan LF; Clouston AD; Walpole ET; Powell EE
J Gastroenterol Hepatol; 1999 Aug; 14(8):801-3. PubMed ID: 10482432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]